Hybrid approach to structure modeling of the histamine H3 receptor: Multi-level assessment as a tool for model verification
暂无分享,去创建一个
[1] A. Sugawara,et al. The expression and function of histamine H3 receptors in pancreatic beta cells , 2014, British journal of pharmacology.
[2] J. Brioni,et al. In-vivo histamine H3 receptor antagonism activates cellular signaling suggestive of symptomatic and disease modifying efficacy in Alzheimer’s disease , 2011, Neuropharmacology.
[3] Yang Zhang,et al. The I-TASSER Suite: protein structure and function prediction , 2014, Nature Methods.
[4] Manfred Burghammer,et al. Structure of bovine rhodopsin in a trigonal crystal form. , 2003, Journal of molecular biology.
[5] B. Trzaskowski,et al. Action of Molecular Switches in GPCRs - Theoretical and Experimental Studies , 2012, Current medicinal chemistry.
[6] J. Schwartz,et al. Determination of the binding mode and interacting amino-acids for dibasic H3 receptor antagonists. , 2013, Bioorganic & medicinal chemistry.
[7] R. Leurs,et al. The Akt/GSK‐3β axis as a new signaling pathway of the histamine H3 receptor , 2007 .
[8] John Dunlop,et al. The role of transmembrane helix 5 in agonist binding to the human H3 receptor. , 2002, The Journal of pharmacology and experimental therapeutics.
[9] Ricardo Márquez-Gómez,et al. Histamine H3 receptor activation counteracts adenosine A2A receptor-mediated enhancement of depolarization-evoked [3H]-GABA release from rat globus pallidus synaptosomes. , 2014, ACS chemical neuroscience.
[10] H. Haas,et al. Histamine in the nervous system. , 2008, Physiological reviews.
[11] A. J. Venkatakrishnan,et al. Diverse activation pathways in class A GPCRs converge near the G-protein-coupling region , 2016, Nature.
[12] P. Blandina,et al. Central histaminergic system and cognition , 2000, Neuroscience & Biobehavioral Reviews.
[13] E. Levin,et al. JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats , 2011, Psychopharmacology.
[14] Saskia Nijmeijer,et al. Molecular determinants of ligand binding modes in the histamine H(4) receptor: linking ligand-based three-dimensional quantitative structure-activity relationship (3D-QSAR) models to in silico guided receptor mutagenesis studies. , 2011, Journal of medicinal chemistry.
[15] J. Klco,et al. Essential role for the second extracellular loop in C5a receptor activation , 2005, Nature Structural &Molecular Biology.
[16] Rob Leurs,et al. Delineation of Receptor‐Ligand Interactions at the Human Histamine H1 Receptor by a Combined Approach of Site‐Directed Mutagenesis and Computational Techniques – or – How to Bind the H1 Receptor , 2005, Archiv der Pharmazie.
[17] N. Oudart,et al. Bronchodilatation of guinea‐pig perfused bronchioles induced by the H3‐receptor for histamine: role of epithelium , 1993, British journal of pharmacology.
[18] J. Wess,et al. Multiple Residues in the Second Extracellular Loop Are Critical for M3 Muscarinic Acetylcholine Receptor Activation* , 2007, Journal of Biological Chemistry.
[19] A. Elofsson,et al. Multi-domain proteins in the three kingdoms of life: orphan domains and other unassigned regions. , 2005, Journal of molecular biology.
[20] J. Ballesteros,et al. G protein-coupled receptor drug discovery: implications from the crystal structure of rhodopsin. , 2001, Current opinion in drug discovery & development.
[21] A. Buschauer,et al. The Extracellular Loop 2 (ECL2) of the Human Histamine H4 Receptor Substantially Contributes to Ligand Binding and Constitutive Activity , 2015, PloS one.
[22] A. Hancock,et al. Molecular modeling and pharmacological analysis of species-related histamine H3 receptor heterogeneity , 2003, Neuropharmacology.
[23] Saskia Nijmeijer,et al. Mapping histamine H4 receptor–ligand binding modes , 2013 .
[24] Matthew P. Repasky,et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.
[25] H. Stark,et al. Chlorophenoxy aminoalkyl derivatives as histamine H(3)R ligands and antiseizure agents. , 2016, Bioorganic & medicinal chemistry.
[26] P Kolb,et al. GPCRdb: the G protein‐coupled receptor database – an introduction , 2016, British journal of pharmacology.
[27] Robert P Bywater,et al. Location and nature of the residues important for ligand recognition in G‐protein coupled receptors , 2005, Journal of molecular recognition : JMR.
[28] J. Emmerich,et al. The European Medicines Agency review of pitolisant for treatment of narcolepsy: summary of the scientific assessment by the Committee for Medicinal Products for Human Use. , 2017, Sleep medicine.
[29] Scott D Bembenek,et al. Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore. , 2006, Journal of molecular graphics & modelling.
[30] Sylvain Crochet,et al. The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders. , 2004, Trends in pharmacological sciences.
[31] Martin J. Lohse,et al. Mutations of Tyr326 in the β2-adrenoceptor disrupt multiple receptor functions , 1996 .
[32] G. V. van Westen,et al. Importance of the extracellular loops in G protein-coupled receptors for ligand recognition and receptor activation. , 2011, Trends in pharmacological sciences.
[33] Stephen M. Husbands,et al. Structural insights into μ-opioid receptor activation , 2015, Nature.
[34] Lei Xie,et al. Using multiple structure alignments, fast model building, and energetic analysis in fold recognition and homology modeling , 2003, Proteins.
[35] Pascal Benkert,et al. QMEAN server for protein model quality estimation , 2009, Nucleic Acids Res..
[36] Francesca Fanelli,et al. Mutagenesis and modelling of the alpha(1b)-adrenergic receptor highlight the role of the helix 3/helix 6 interface in receptor activation. , 2002, Molecular pharmacology.
[37] H. Kotani,et al. Enhanced Histaminergic Neurotransmission and Sleep-Wake Alterations, a Study in Histamine H3-Receptor Knock-Out Mice , 2013, Neuropsychopharmacology.
[38] Holger Stark,et al. Histamine H3 receptor antagonists go to clinics. , 2008, Biological & pharmaceutical bulletin.
[39] Zhexin Xiang,et al. Homology-Based Modeling of Protein Structure , 2007 .
[40] Hiroki Yoneyama,et al. Synthesis and evaluation of N-alkyl-S-[3-(piperidin-1-yl)propyl]isothioureas: high affinity and human/rat species-selective histamine H(3) receptor antagonists. , 2013, Bioorganic & medicinal chemistry letters.
[41] Claudio N. Cavasotto,et al. Ligand and Decoy Sets for Docking to G Protein-Coupled Receptors , 2012, J. Chem. Inf. Model..
[42] Ruben Abagyan,et al. Structure of the human histamine H1 receptor complex with doxepin , 2011, Nature.
[43] A. Strasser,et al. Role of the second and third extracellular loops of the histamine H4 receptor in receptor activation , 2011, Naunyn-Schmiedeberg's Archives of Pharmacology.
[44] K. Currie,et al. Regulation of Ca(V)2 calcium channels by G protein coupled receptors. , 2013, Biochimica et biophysica acta.
[45] Thorsten Meinl,et al. KNIME: The Konstanz Information Miner , 2007, GfKl.
[46] D. Higgins,et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega , 2011, Molecular systems biology.
[47] J. Schwartz,et al. Highly potent and selective ligands for histamine H3-receptors , 1987, Nature.
[48] Dorota Latek,et al. A Hybrid Approach to Structure and Function Modeling of G Protein-Coupled Receptors , 2016, J. Chem. Inf. Model..
[49] K. Kieć‐Kononowicz,et al. New developments around histamine H3 receptor antagonists/inverse agonists: a patent review (2010 – present) , 2014, Expert opinion on therapeutic patents.
[50] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[51] Min Zhang,et al. Pharmacological Properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological Characterization and Broad Preclinical Efficacy in Cognition and Schizophrenia of a Potent and Selective Histamine H3 Receptor Antagonist , 2005, Journal of Pharmacology and Experimental Therapeutics.
[52] Gaetano T Montelione,et al. Evaluating protein structures determined by structural genomics consortia , 2006, Proteins.
[53] C. Rizzo,et al. Coordination of Histamine H3 Receptor Antagonists with Human Adrenal Cytochrome P450 Enzymes , 2002, Pharmacology.
[54] C. Humblet,et al. Modeling G protein‐coupled receptors for structure‐based drug discovery using low‐frequency normal modes for refinement of homology models: Application to H3 antagonists , 2010, Proteins.
[55] Xavier Deupi,et al. Structural insights into agonist-induced activation of G-protein-coupled receptors. , 2011, Current opinion in structural biology.
[56] H. Stark,et al. Refined Docking as a Valuable Tool for Lead Optimization: Application to Histamine H3 Receptor Antagonists , 2008, Archiv der Pharmazie.
[57] Kurt Kristiansen,et al. Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. , 2004, Pharmacology & therapeutics.
[58] William A. Goddard,et al. Structure-Based Prediction of Subtype Selectivity of Histamine H3 Receptor Selective Antagonists in Clinical Trials , 2011, J. Chem. Inf. Model..
[59] G. Abbott,et al. Cardioprotective Effect of Histamine H3-Receptor Activation: Pivotal Role of Gβγ-Dependent Inhibition of Voltage-Operated Ca2+ Channels , 2008, Journal of Pharmacology and Experimental Therapeutics.
[60] Torsten Schwede,et al. BIOINFORMATICS Bioinformatics Advance Access published November 12, 2005 The SWISS-MODEL Workspace: A web-based environment for protein structure homology modelling , 2022 .
[61] H P Rang,et al. Rang and Dale's pharmacology , 2012 .
[62] The Uniprot Consortium,et al. UniProt: a hub for protein information , 2014, Nucleic Acids Res..
[63] J. Schwartz,et al. Efficacy of the histamine 3 receptor (H3R) antagonist pitolisant (formerly known as tiprolisant; BF2.649) in epilepsy: Dose-dependent effects in the human photosensitivity model , 2013, Epilepsy & Behavior.
[64] J. Schwartz,et al. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor , 1983, Nature.
[65] H. Timmerman,et al. Isothiourea analogues of histamine as potent agonists or antagonists of the histamine H3-receptor , 1992 .
[66] María Martín,et al. UniProt: A hub for protein information , 2015 .
[67] R. Leurs,et al. Molecular aspects of the histamine H3 receptor. , 2007, Biochemical pharmacology.
[68] Gerhard Klebe,et al. DSX: A Knowledge-Based Scoring Function for the Assessment of Protein-Ligand Complexes , 2011, J. Chem. Inf. Model..
[69] Yongchao Liu,et al. MSAProbs-MPI: parallel multiple sequence aligner for distributed-memory systems , 2016, Bioinform..
[70] Jakub Jończyk,et al. Therapeutic strategies for Alzheimer’s disease in clinical trials , 2016, Pharmacological reports : PR.
[71] M. Jackson,et al. Cloning and functional expression of the human histamine H3 receptor. , 1999, Molecular pharmacology.
[72] P. Maruff,et al. A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease. , 2014, Current Alzheimer Research.
[73] M. Fidock,et al. Maximizing serendipity: strategies for identifying ligands for orphan G-protein-coupled receptors. , 2003, Current opinion in pharmacology.
[74] James M Aramini,et al. Assessment of template‐based protein structure predictions in CASP10 , 2014, Proteins.
[75] Ben M. Webb,et al. Comparative Protein Structure Modeling Using MODELLER , 2016, Current protocols in bioinformatics.
[76] M. Williams,et al. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist. , 2004, Biochemical pharmacology.
[77] A. Hancock. H3 receptor antagonists/inverse agonists as anti-obesity agents. , 2003, Current opinion in investigational drugs.
[78] Holger Stark,et al. High constitutive activity of native H3 receptors regulates histamine neurons in brain , 2000, Nature.
[79] J. Meiler,et al. BCL::Score—Knowledge Based Energy Potentials for Ranking Protein Models Represented by Idealized Secondary Structure Elements , 2012, PloS one.
[80] Roland L Dunbrack,et al. Assessment of template‐based modeling of protein structure in CASP11 , 2016, Proteins.
[81] Richard D. Taylor,et al. Improved protein–ligand docking using GOLD , 2003, Proteins.
[82] Gerhard Klebe,et al. Comparison of Automatic Three-Dimensional Model Builders Using 639 X-ray Structures , 1994, J. Chem. Inf. Comput. Sci..